DOCS VALVE®Transcatheter aortic Valve Replacement System (in Development)

The prevalence of valve disease in China is 3.8%, about 25 million people. According to industry reports, the number of patients with aortic stenosis and aortic regurgitation in China in 2022 is about 4.65 million and 4.05 million, respectively. With the aging trend of China's population, heart valve disease will increase, if not timely standardized treatment, the mortality rate of 2 years can reach 50%, and the mortality rate of 5 years is as high as 97%.

  • 产品网页banmo.jpg

Product Description

Product characteristics

This product is suitable for the treatment of aortic stenosis and reflux dual indications, can achieve safe and smooth release without rapid pacing, making the surgical process safer and simpler.



Product Consulting

If you encounter any questions in browsing our company's website or are interested in our products, please contact us in time. We will treat your every visit, every phone call, every email and every message with a sincere attitude. We sincerely look forward to your visit and cooperation!

Submit Message